Re-evaluating the effect of fenfluramine treatment on regurgitation of cardiac valves in simple obesity patients

沈稚舟,刘志民,邹大进,单玉明,杨叶虹,胡吉,姜文宇,张琳,张朝云,石勇铨,刘颖,沈玉美,高从容,徐茂锦,赵宝珍

DOI: https://doi.org/10.3760/j.issn:1000-6699.2003.03.009

2003-01-01

Abstract:Objective To r-evaluate the effect of fenfluramine treatment on regurgitation of cardiac valves in patients with obesity, which was a controversial issue. Methods This was a randomized, single-blind, multi-center trial with parallel control groups of sibutramine and placebo. A total of 183 patients with obesity aged 18-60 years received fenfluramine (64 cases) , sibutramine (63 cases) and placebo (56 cases) for 3 months. Cardiac valve regurgitation was observed by echocardiography. Results There were respectively 1,0 and 0 cases showing significant improvement in mitral regurgitation in the 3 groups, but none had a significant deterioration. And there were respectively 3, 0 and 1 cases showing significant improvement of regurgitation from aortic valves, while the cases with significant deterioration were 2, 0 and 0 respectively. There was no statistical difference among the 3 groups. The body weight loss in therapeutic groups (especially the fenfluramine group) was more significant than that in the placebo group. There was no significant difference in the regurgitation of the 2 valves among the 3 groups. Conclusion This study does not support the verdict that a short-term administration of fenfluramine with an ordinary dosage will cause regurgitation of the valves in patients with obesity.